Crinetics Pharmaceuticals
CRNX
CRNX was delisted on the 31st of August, 2026.
243 hedge funds and large institutions have $4.46B invested in Crinetics Pharmaceuticals in 2026 Q1 according to their latest regulatory filings, with 49 funds opening new positions, 116 increasing their positions, 59 reducing their positions, and 41 closing their positions.
97% more repeat investments, than reductions
Existing positions increased: 116 | Existing positions reduced: 59
20% more funds holding in top 10
Funds holding in top 10: 5 → 6 (+1)
20% more first-time investments, than exits
New positions opened: 49 | Existing positions closed: 41
1% more funds holding
Funds holding: 240 → 243 (+3)
0.34% less ownership
Funds ownership: 117.6% → 117.26% (-0.34%)
14% less capital invested
Capital invested by funds: $5.19B → $4.46B (-$737M)
18% less call options, than puts
Call options by funds: $2.55M | Put options by funds: $3.1M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
+$146M |
| 2 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$84M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$65.5M |
| 4 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$62.8M |
| 5 |
SCM
Suvretta Capital Management
New York
|
+$46.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$109M |
| 2 |
PBA
Paradigm Biocapital Advisors
New York
|
-$103M |
| 3 |
Jennison Associates
New York
|
-$16.8M |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$15M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
-$10.9M |
CRNX Hedge Fund Activity: Q1 2026 in Review
243 of the 8,191 institutional investors tracked by Wall St. Rank reported a position in Crinetics Pharmaceuticals (CRNX) for Q1 2026, worth a combined $4.46B — down 14% from $5.19B a quarter earlier.
Buyers outnumbered sellers: 49 funds opened new CRNX positions and 41 closed out — a net gain of 8 holders — while 116 added to existing stakes and 59 trimmed.
The largest buyer was Bellevue Group, adding an estimated $146M. The largest seller was Point72 Asset Management, exiting entirely with an estimated $109M sold.
- 243 institutional investors held Crinetics Pharmaceuticals (CRNX) as of Q1 2026, up from 240 in Q4 2025.
- Funds reported $4.46B of Crinetics Pharmaceuticals stock for Q1 2026, down 14% quarter-over-quarter.
- 49 funds opened new Crinetics Pharmaceuticals positions in Q1 2026 and 41 closed out, a net change of +8 holders.
- The largest Crinetics Pharmaceuticals buyer in Q1 2026 was Bellevue Group, an estimated $146M added.
- The largest Crinetics Pharmaceuticals seller in Q1 2026 was Point72 Asset Management, an estimated $109M sold.
Based on aggregated 13F filings for Q1 2026.